A Colorado Concentrate Passed Its Pesticide Test, Then Failed It. Two Weeks Later the Recall Doubled.

The Colorado Department of Revenue and the Colorado Department of Public Health and Environment issued the original advisory on July 15, 2026 for regulated marijuana concentrate produced by Colorado Medical Processing LLC, doing business as Colorado’s Best Dabs. The product had passed testing, then was retested because of laboratory testing concerns identified during an investigation, and on retest exceeded the limit for chlorfenapyr set in Colorado Marijuana Rule 4-215.

The July 31 expansion is the part most coverage missed. It added vaporizer delivery devices to the advisory, widened the sales window from September 18 to November 24, 2025 back to August 1 to November 24, 2025, and raised the number of affected stores from 11 to 24. A patient who read the July story and concluded their cart was unaffected may have read it before the cart was added.

Patients who moved to the regulated market did so on a promise of testing. When a batch passes and later fails, that promise has a gap in it, and patients deserve an honest account of where the gap is rather than reassurance or alarm.

The practical skill this story teaches is small and durable. Every regulated cannabis package in Colorado carries the producer’s license number and a production batch number. A recall notice lists exactly those two things. A patient who knows to look at them can resolve in thirty seconds a question that otherwise produces a week of worry.

The operative document is the expanded advisory dated July 31, 2026, not the original. It covers regulated marijuana concentrate and vaporizer delivery devices produced under manufacturer licenses 404R-00354 and 404-00383. The identified batches are 3759R, an RSO concentrate, and 3639R, a Peach Sour D Liquid Diamond one gram cartridge.

Affected product was sold between August 1, 2025 and November 24, 2025 at 24 stores. The state’s instruction to anyone still holding it is unchanged: destroy it, or return it to the store where it was purchased for proper disposal. Anyone who experienced adverse health effects after consuming it should seek medical attention and report the event to the Marijuana Enforcement Division.

As of September 13, 2026 the advisory remains posted and has not been further expanded or withdrawn. Colorado does not issue closure notices for health and safety advisories, so a patient checking the state’s advisory page will find this one listed alongside thirteen others issued in 2026.

Chlorfenapyr is a broad-spectrum pyrrole insecticide and a pro-insecticide, meaning it is metabolized in the body to an active compound, tralopyril, which uncouples oxidative phosphorylation. A 2026 review of acute human exposure in the Journal of Applied Toxicology describes a poisoning course unlike most agricultural chemicals: a latency period that can extend to fourteen days, gradual deterioration over hours to days, and delayed neurological symptoms with a high mortality rate. Hyperthermia is the serious clinical sign. Laboratory findings commonly include elevated creatine kinase, hepatic aminotransferases, and lactate dehydrogenase. There is no specific antidote, and treatment is supportive.

That literature describes acute high-dose ingestion, usually in self-harm or occupational contexts, not inhalation of a contaminated cannabis concentrate. The doses are not comparable and it would be wrong to suggest otherwise. What the toxicology does explain is why a regulator treats a chlorfenapyr exceedance as a threat to public health rather than a paperwork problem, and why the delayed presentation described in that literature argues against reassuring a symptomatic patient on the basis of an unremarkable first day.

No illnesses have been publicly linked to this recall. The advisory does not report an exposure level, a number of units sold, or any adverse event, and none of those figures are available. That is the honest state of the record.

Both the original and the expanded advisory use the same phrase: the batches initially passed testing but were later subjected to additional testing due to laboratory testing concerns identified during an investigation. That sentence is doing a great deal of work.

It means the recall was not triggered by a consumer complaint, an adverse event, or a routine surveillance sample. It was triggered by scrutiny of the testing laboratory itself, and the product was pulled only because someone went back and retested it. Any batch that a compromised laboratory cleared and that nobody thought to retest would still be in circulation and would look, on paper, like a passing product.

That is the structural lesson, and it is not unique to Colorado. A regulated market’s safety claim rests on the integrity of the laboratories that certify it, and laboratory oversight is the least visible part of the system to a patient standing at a counter. The certificate of analysis a dispensary shows a customer is only as good as the lab that issued it.

Colorado posted fourteen health and safety advisories between January and September 10, 2026. Several involve pesticides. The pattern worth noticing is not the count but the behavior of individual advisories over time.

Sofa King Medicinal Wellness Products LLC, doing business as SKM, had an advisory issued July 2, 2026 for vaporizer delivery devices exceeding limits for bifenazate and metalaxyl. It was expanded on July 31. It was updated again on August 21 after the Division identified that devices which had been recalled and quarantined were nonetheless sold to consumers on August 2, 2026, and the sales window for that advisory now runs from March 15 to August 2, 2026.

The most recent advisory, on September 10, 2026, concerns microbial contamination in product from Navajo Management LLC doing business as Locol Love. For a patient, the takeaway from the sequence is procedural. An advisory you read in July may cover different products in August. Checking once is not the same as checking.

Every regulated marijuana package in Colorado must carry a label listing, at minimum, the license number of the business that produced it and the production batch number assigned to it. Those are the two identifiers a health and safety advisory lists. Matching them is the entire exercise.

The practical habits follow from that. Keep the original packaging until a product is finished rather than decanting concentrate or loose flower into an unlabeled container. Photograph the label if you plan to discard the box. Note roughly when you purchased, since advisories are bounded by sales windows. Check the state’s advisory page when you hear about a recall rather than relying on a news summary, because the summary may predate an expansion.

For clinicians, the corresponding move is to ask about route and timing rather than only about substance. Inhaled concentrate and a vaporizer cartridge are the formats at issue here, and a patient reporting new respiratory symptoms, unexplained fever, muscle pain, or profound fatigue after using a specific cartridge deserves a question about which product, purchased when, and whether the packaging still exists. That question costs nothing and occasionally changes a workup.

The regulatory record is strong and directly readable. The license numbers, production batches, sales windows, store counts, and contaminant are stated in the state’s own advisories, and the expansion history is visible on Colorado’s published advisory page. Nothing here depends on a secondary account.

The clinical record is empty. No adverse events have been publicly tied to these batches, no exposure level has been reported, and no analysis exists of what inhaling a chlorfenapyr-contaminated concentrate delivers to a user. The toxicology literature cited here describes a different exposure route at a different magnitude and should be read as an explanation of why the limit exists, not as a prediction of what any consumer experienced.

It would be easy to write this story as evidence that regulated cannabis is unsafe. That conclusion does not follow. The reason anyone knows about these batches is that a regulated system requires labeling, batch tracking, and laboratory certification, and then audited the laboratory. An unregulated product with the same contamination generates no advisory because there is nothing to recall and no batch to name.

The opposite conclusion, that the system worked, is also too comfortable. The product cleared testing, reached at least 24 stores, and was consumed for months before anyone looked again. A system that catches a problem nine months after the last sale has caught it, in a sense that offers limited consolation to whoever used it in October.

This advisory does not show that anyone was harmed, how much chlorfenapyr was present, how much product was sold or consumed, or how contamination reached the batch. It does not establish whether the laboratory concerns that prompted retesting were error, misconduct, or something else, and the state has not characterized them publicly.

It also does not show how widely the underlying testing problem reaches. The advisories name specific batches that were retested. They say nothing about batches from the same period that were certified by the same process and never revisited.

Pesticide contamination in cannabis sits in a regulatory gap that predates any state program. Because cannabis remains federally controlled, the Environmental Protection Agency has not established residue tolerances for it the way it has for food crops, so states set their own allowed and prohibited lists and their own action limits. Colorado’s Rule 4-215 is one such list, and chlorfenapyr is not on the permitted side of it.

That gap has a practical consequence for interpretation. When a state reports a pesticide exceedance in cannabis, there is no federal tolerance to compare it against and no established dietary or inhalation risk assessment for that route. The finding is a rule violation with a clear regulatory meaning and an uncertain clinical one, and those two things should not be conflated.

The part of this that stays with me is not chlorfenapyr. It is the sentence about laboratory testing concerns identified during an investigation. Patients who moved into the legal market did it for exactly one reason, which is that somebody tests the product. When the testing itself is the thing under investigation, the entire value proposition is in question, and no amount of reassurance about this particular batch addresses that.

What I tell patients is unglamorous. Keep the box until the jar is empty. Take a picture of the label. Know roughly when you bought it. If a recall comes out, you will spend thirty seconds instead of three days wondering. And if you develop something unexplained after using a specific product, bring the packaging to the visit. I cannot do much with a patient’s memory of a cartridge. I can do quite a lot with a batch number.

The Colorado’s Best Dabs advisory is active and larger than it was in July, now covering concentrate batch 3759R and cartridge batch 3639R sold between August 1 and November 24, 2025 at 24 stores. Check any Colorado concentrate or cartridge from that window against license numbers 404R-00354 and 404-00383, destroy or return a match, and treat the label on every regulated package as the thing that makes a recall notice usable.

Carry forward the mechanism rather than the product name. A batch can pass and later fail, a recall can double two weeks after it is announced, and the trigger here was scrutiny of a testing laboratory rather than a sick consumer. The claim not to carry forward is that anyone was poisoned, because nothing in the public record establishes that.